Abstract
Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted a clinical study to evaluate the efficacy and safety of IRIS plus bevacizumab as first-line therapy for metastatic colorectal cancer. Methods: Forty metastatic colorectal cancer patients were enrolled in this phase II study. All patients received irinotecan (80 mg/m2) and bevacizumab (7 mg/kg) on days 1 and 15 and S-1 (40-60 mg twice daily) on days 1-21 of a 5-week repeated cycle. Results: The response rate was 47.4% [95% confidence interval (CI) 31.5-63.2], progression-free survival was 11.9 months (95% CI 9.4-16.8), and overall survival was 23.4 months (95% CI 19.0-inf). The only grade 3 hematological toxicity was neutropenia (16%) and the incidences of grade 3 nonhematological toxicity were low at <10%, other than diarrhea (10.9%). Conclusion: In this clinical study, we revealed IRIS plus bevacizumab to be a promising first-line regimen for metastatic colorectal cancer with a low incidence of serious toxicities, in which favorable response rates and extension of survival time can be expected.
| Original language | English |
|---|---|
| Pages (from-to) | 317-322 |
| Number of pages | 6 |
| Journal | Oncology (Switzerland) |
| Volume | 85 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1 2013 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
A phase ii study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer. / Mizushima, Tsunekazu; Ide, Yoshito; Murata, Kohei; Ohashi, Ichiro; Yasumasa, Keigo; Fukunaga, Mutsumi; Takemoto, Hiroyoshi; Tamagawa, Hiroshi; Hasegawa, Junichi; Hata, Taishi; Takemasa, Ichiro; Ikeda, Masataka; Yamamoto, Hirofumi; Sekimoto, Mitsugu; Nezu, Riichiro; Doki, Yuichiro; Mori, Masaki.
In: Oncology (Switzerland), Vol. 85, No. 6, 01.12.2013, p. 317-322.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A phase ii study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer
AU - Mizushima, Tsunekazu
AU - Ide, Yoshito
AU - Murata, Kohei
AU - Ohashi, Ichiro
AU - Yasumasa, Keigo
AU - Fukunaga, Mutsumi
AU - Takemoto, Hiroyoshi
AU - Tamagawa, Hiroshi
AU - Hasegawa, Junichi
AU - Hata, Taishi
AU - Takemasa, Ichiro
AU - Ikeda, Masataka
AU - Yamamoto, Hirofumi
AU - Sekimoto, Mitsugu
AU - Nezu, Riichiro
AU - Doki, Yuichiro
AU - Mori, Masaki
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted a clinical study to evaluate the efficacy and safety of IRIS plus bevacizumab as first-line therapy for metastatic colorectal cancer. Methods: Forty metastatic colorectal cancer patients were enrolled in this phase II study. All patients received irinotecan (80 mg/m2) and bevacizumab (7 mg/kg) on days 1 and 15 and S-1 (40-60 mg twice daily) on days 1-21 of a 5-week repeated cycle. Results: The response rate was 47.4% [95% confidence interval (CI) 31.5-63.2], progression-free survival was 11.9 months (95% CI 9.4-16.8), and overall survival was 23.4 months (95% CI 19.0-inf). The only grade 3 hematological toxicity was neutropenia (16%) and the incidences of grade 3 nonhematological toxicity were low at <10%, other than diarrhea (10.9%). Conclusion: In this clinical study, we revealed IRIS plus bevacizumab to be a promising first-line regimen for metastatic colorectal cancer with a low incidence of serious toxicities, in which favorable response rates and extension of survival time can be expected.
AB - Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted a clinical study to evaluate the efficacy and safety of IRIS plus bevacizumab as first-line therapy for metastatic colorectal cancer. Methods: Forty metastatic colorectal cancer patients were enrolled in this phase II study. All patients received irinotecan (80 mg/m2) and bevacizumab (7 mg/kg) on days 1 and 15 and S-1 (40-60 mg twice daily) on days 1-21 of a 5-week repeated cycle. Results: The response rate was 47.4% [95% confidence interval (CI) 31.5-63.2], progression-free survival was 11.9 months (95% CI 9.4-16.8), and overall survival was 23.4 months (95% CI 19.0-inf). The only grade 3 hematological toxicity was neutropenia (16%) and the incidences of grade 3 nonhematological toxicity were low at <10%, other than diarrhea (10.9%). Conclusion: In this clinical study, we revealed IRIS plus bevacizumab to be a promising first-line regimen for metastatic colorectal cancer with a low incidence of serious toxicities, in which favorable response rates and extension of survival time can be expected.
UR - http://www.scopus.com/inward/record.url?scp=84892176352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892176352&partnerID=8YFLogxK
U2 - 10.1159/000356018
DO - 10.1159/000356018
M3 - Article
VL - 85
SP - 317
EP - 322
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 6
ER -